Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab Neoadjuvant and Maintenance Therapy in Advanced Cervical Cancer
ChiCTR2600126576Phase 4Not yet recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Hubei Cancer Hospital. Primary endpoints: Progression-free survival and Objective response rate of neoadjuvant therapy. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600126576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126576.